Representation improving but not solved—Black patients still underrepresented in recent HS trials
A review of ClinicalTrials.gov trials for hidradenitis suppurativa initiated between June 2020 and December 2024 identified five trials enrolling 411 participants. White/Caucasian participants comprised 68.4% (n=281) and Black/African American participants 22.6% (n=93); the proportion of Black participants rose significantly compared with 2008–2020 trials. Most U.S. trial sites (38 sites, 59.3%) were based in cities with moderate to high Black populations, suggesting site selection may be improving geographic access. Despite this progress, the authors note persistent underrepresentation of Black patients relative to the known burden of HS in skin of color populations.
What’s the takeaway? These findings signal cautious optimism: trial demographics are shifting toward greater inclusion, but clinicians should remain mindful of potential limits to external validity when applying trial results to diverse patients. Consider discussing trial opportunities with eligible patients, support equitable recruitment, and factor population representation into treatment counseling and expectations.
This is a must-read article!
J Drugs Dermatol. 2025;24(12) doi:10.36849/JDD.9060
Blog write-up assisted by AI
